Podcasts about vanguards

“Ease of use is what drives adoption,” Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about what can fuel further insulin-pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm, now approved for both type 1 and type 2 diabetes. The conversation also touches on the company’s international market strategy, value-based reimbursement and future product development, including the tubeless Sigi.See omnystudio.com/listener for privacy information.

“We didn’t start Model to launch a company — we started it because no one else met our standards,” says Dr. Daniel Haders II, CEO and founder of Model Medicines. On this episode of Vanguards of Health Care, Haders speaks with Bloomberg Intelligence analyst Andrew Galler about building an AI-native drug discovery engine capable of identifying cryptic binding pockets and designing first-in-class drugs. They unpack why hit rates and novelty must go hand-in-hand, an overview of the company’s pan-antiviral MDL-001, and why generalizability — not reinforcement learning — is the true litmus test for AI in biotech.See omnystudio.com/listener for privacy information.

“The most effective therapies for solid tumors are also the most toxic — and we need to fix that,” says Dr. John Connolly, chief scientific officer of the Parker Institute for Cancer Immunotherapy. In this episode of the Vanguards of Health Care podcast, Connolly tells Bloomberg Intelligence pharmaceutical analyst Sam Fazeli why managing toxicity is the key to unlocking CAR-T’s potential in solid tumors. They explore the rise of in vivo cell therapies, evolving views on the tumor microenvironment and why foundational cancer vaccines may shape the future of all immunotherapy. Connolly also shares the clinical trials he’s watching closely, the ones that could flip the script on cancer care.See omnystudio.com/listener for privacy information.

On this episode of the Astonishing Healthcare podcast, Bloomberg Intelligence's Jonathan Palmer (Sr. Equity Analyst & Team Lead, Healthcare) joins us in the studio for a discussion about the work his team does and the evolving landscape of health tech. Palmer notes interest in Hinge Health's potential IPO and how the market's receptivity to tech-enabled healthcare companies has improved recently. While these companies face pressure to demonstrate profitability amid evolving market dynamics, there's optimism about innovation on several fronts. He also explains the impact of health policy uncertainty and questions about what the FDA, FTC, DOJ, and CMS will do on investors' ability to place bets: ambiguity causes market hesitation, and investors gravitate toward safe havens.The discussion also covers areas of focus for 2025, including:Palmer's favorite Vanguards of Healthcare podcast episodes and why he enjoys speaking with private company CEOs and venture capital leadersBiopharma Innovation, including GLP-1s, oncology readoutsMedTech Advancements like surgical robotics, cardioablation, and evolving insulin delivery systemsCapital Spending Concerns as US providers and China's healthcare sector are under scrutinyHealthcare Services: online pharmacy growth and Medicare Advantage trendsReference Materials Courtesy of Bloomberg IntelligenceNorth America Managed-Care Policy OutlookN.A. Health-Care Tech, Distribution: 2025 OutlookRelated ContentVanguards of Health Care: How Capital Rx is Fixing America's Broken Drug PricingAH057 - How First-Movers are Taking Control of their Health Plans in 2025, with Jeff HoganAH047 - What Project 2025, RFK Jr., and Dr. Oz Could Mean for the Business of Healthcare Under TrumpAH046 - What's Hot In and Around the Pharmacy Supply Chain, with RSM's Tom EveganFor more information about Capital Rx and this episode, please visit Capital Rx Insights.

Cardiac monitoring “is a space that hasn’t seen disruption or innovation for 50 to 60 years, and we’re trying to disrupt that with our AI-powered Zio platform,” iRhythm CEO Quentin Blackford tells Bloomberg Intelligence. “And really, the focus is on how do we enable an earlier, more accurate diagnosis while reducing the workflow effects for our physicians?” In this episode of the Vanguards of Health Care podcast, Blackford sits down with BI analyst Matt Henriksson to talk about iRhythm, how its Zio-platform technology powered by its AI network allows patients to be monitored without disrupting their everyday lives, and how its clinical data could support a more proactive screening of patients to find arrhythmias before a catastrophic adverse event occurs.See omnystudio.com/listener for privacy information.

The crew delve more into vanguards, and discover that Colin belongs in a museum.

“We decided to come to the table with a health-plan model that enables what we like to call radical affordability,” said Ashok Subramanian, CEO and co-founder of Centivo, in this episode of the Vanguards of Health Care podcast. Subramanian joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Centivo’s approach to self-funded employer plans focuses on reducing costs without sacrificing quality. By leveraging direct-provider partnerships and emphasizing primary care, the company aims to keep 75% of members’ out-of-pocket costs below $200 per year. The conversation covers how Centivo differentiates itself from traditional insurers, its expansion into new markets, and how it helps employers navigate high-cost treatments like GLP-1 drugs while maintaining sustainable benefits for workers. See omnystudio.com/listener for privacy information.

JR has drummed on over 200 US Billboard Hot 100 songs and 50 Grammy winning tunes. He was in Rufus w/ Chaka Khan in the late 70s/early 80s, has released two solo albums, written for soundtracks, produced other artists, and has led various combos over the years. He is currently promoting his auto-biography King of the Groove. We discuss "Gonna Be Alright" from The Bronx, USA soundtrack (2020), "Flight 81" from his first solo album, Funkshui (2004), and "You're Really Out of Line" by Rufus from Seal in Red (1983). End song: "Tal Shia" by SRT from Vanguards of Groove (2023). Intro: "Higher Love" by Steve Winwood (1986). More at johnjrrobinson.com. Hear more Nakedly Examined Music. Support us on Patreon.

“As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it’s leveraging AI,” said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci’s generative AI platform and developing best-in-class biologics.See omnystudio.com/listener for privacy information.

"The conversation is the treatment in behavioral health, but clinicians spend too much time documenting instead of caring,” says Alon Joffe, CEO and cofounder of Eleos Health, in this episode of the Vanguards of Health Care podcast. Joffe joins Bloomberg Intelligence analyst Jonathan Palmer to discuss how Eleos is revolutionizing behavioral health care with AI-driven solutions that reduce administrative burdens by 80% while enhancing clinical outcomes. He shares how Eleos leverages multimodal AI to automate documentation and improve decision-making, enabling clinicians to provide better care. The conversation explores Eleos’ expansion into psychiatry, substance-use treatment and long-term care, as well as its vision to become the AI-native operating system for compassionate care.See omnystudio.com/listener for privacy information.

“There’s no digital feedback loop in health care, you have it in Tesla, in Netflix, in Amazon — but not in the industry that impacts every life,” Terry Myerson, CEO of Truveta, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Myerson joins BI analyst Jonathan Palmer to discuss Truveta’s mission to aggregate and analyze health data across 30 major US health systems, covering one-third of Americans. He details the company’s work in regulatory-grade safety and efficacy research, the launch of the Truveta Genome Project with partners like Regeneron and Illumina, and the power of AI-driven insights to accelerate medical discovery. The conversation explores Truveta’s efforts to address data fragmentation, privacy, and interoperability challenges that must be solved to revolutionize patient care and life sciences.See omnystudio.com/listener for privacy information.

Can you retire with just one dividend fund and could Vanguard's High Dividend ETF fund ticker symbol VYM be that Fund?Tickerdata Referral Link: https://tickerdata.com/?aff=pZVGdNQuality At A Fair Price - Newsletter: https://qualityatafairprice.substack.com/VYM Article: https://qualityatafairprice.substack.com/p/would-vym-be-enough-for-your-retirementM1 Finance referral link:https://m1.finance/UNbCUpuP36lmSubscribe to my channel: https://www.youtube.com/c/LongacresFinancePatreon: https://www.patreon.com/LongacresFinanceDisclaimer: This video is intended for entertainment purposes only and should not be taken as investment advice.#dividendincome #dividends #schd #dividendgrowthinvesting

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/east-asian-studies

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/biography

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/economics

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/finance

As Wall Street swooned and boomed through the last decade, our livelihoods have—now more than ever—come to rely upon the good sense and risk appetites of a few standout investors. And amidst the BlackRocks, Vanguards, and Berkshire Hathaways stands arguably the most iconoclastic of them all: SoftBank's Masayoshi Son. In Gambling Man: The Wild Ride of Japan's Masayoshi Son (Atria, 2024), the first Western biography of Son, the self-professed unicorn hunter, we go behind the scenes of the world's most monied halls of power in New York, Tokyo, Silicon Valley, Saudi Arabia, and beyond to see how Son's firm SoftBank has defied conventional wisdom and imposing odds to push global tech and commerce into the future. From the dizzying highs of Uber, DoorDash, and Slack to the epic lows of WeWork and tech-infused dogwalking app Wag Son and SoftBank have been at the center of cutting-edge capitalism's absolute peaks and valleys. In the process, Son, son of a pachinko kingpin who grew up in a slum in Japan, has been a hero, a villain, and even a meme-ified hero to the internet tech- and finance-bro set all at once. Based on in-depth research and eye-opening interviews, Gambling Man is an unforgettable character study and alarming true story of twenty-first-century commerce that will stick with you long after you turn the final page. Lionel Barber is the former editor of the Financial Times. As editor, he interviewed many of the world's leaders in business and politics, including US Presidents Barack Obama and Donald Trump, Russian President Vladimir Putin, Chancellor Angela Merkel of Germany, and Indian Prime Minister Narendra Modi. Barber has co-written several books and has lectured widely on foreign policy, transatlantic relations, and economics. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/japanese-studies

"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going to be massively compressed," Dr. Tony Wood, Chief Scientific Officer at GSK, explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wood joins BI analyst Sam Fazeli to address the disconnect between market expectations for its future drugs in the context of GSK's R&D strategy and technology leverage. The company has five potential new drug approvals in 2025 and sees its early stage investments in AI and ML holding huge potential to catalyze future drug discovery and development.See omnystudio.com/listener for privacy information.

“We sit at the intersection of those large-scale incumbents and entrepreneurs, to help bridge the gap,” Josh Flum, managing partner at LRVHealth, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Flum joins BI analyst Jonathan Palmer to discuss how LRV’s purpose-built model looks to identify and capitalize on durable long-term trends emerging in health care. With only strategic investors as limited partners, LRV believes it has a differentiated perspective on where the market is headed. The conversation delves into the evolution of pharmacy services and why it’s important to build high-performing teams. The exchange wraps up with the state of the IPO market and key takeaways from the JPMorgan Healthcare conference.See omnystudio.com/listener for privacy information.

“The average benefit value for supplemental benefits was about $155 per member. Five years later, it was over $1,500 per member,” Robby Knight, CEO and cofounder of Soda Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Knight joins BI analyst Jonathan Palmer for a wide-ranging discussion on the rapid evolution of the supplemental-benefits market and the challenges Soda faced in building in a new platform that creates incentives for members, retail partners and plan sponsors. The conversation touches on why Medicare Advantage plans were in an arms race to offer unsustainable benefits, why the correction is an opportunity for the company and how the future will bring optimized benefits at the member level.See omnystudio.com/listener for privacy information.

Episode 45 - Murdock and Marvel: 1997 Part 2 We've got a pretty quiet week in comic terms, partly because everything has gone completely to the dogs, and there is a lot less happening than there was a few years ago.  Still, I was surprised to find that 1997 had some pretty great things going on under the surface!  This is part 2 of the podcast. that will feature the year in Daredevil, the Spotlight story and the Takeaway for 1997.   The Year in Daredevil  Appearances: Daredevil #360-370, Daredevil #-1, Adventures of Spider-Man #10, Bug #1, Code of Honor #2-4, Punisher #17-18, Venom: On Trial #1-3, Marvel Valentine Special #1, Silver Surfer #128, Essential Spider-Man #2, Electra #-1, Ka-Zar #5 and 8, Uncanny Origins #13, Elektra #10-11 and 13, Marvel Heroes & Legends 1997 #1, Spider-Man El Hombre Arana #30, Spider-Man Unlimited #18, Thunderbolts #8 along with Daredevil/Batman, Untold Tales of Spider-Man '97, Kingpin, Origin of Marvel Comics Revised Edition and Son of Origins of the Marvel Comics Revised Edition graphic novels  Writing: Karl Kesel (#360-364), Joe Kelly (#365-370 and #-1)  Pencils: Cary Nord (#360-362, 364-365), Gene Colan (#363, -1, 366-368, 370), Ariel Olivetti (#369)  Inks: Matt Ryan (#360-362, 364-365, -1), Cam Smith and Paul Neary (#363), Al Williamson (#366), Bud LaRosa (#367-368, 370), Pier Brito (#369)  The year begins with Daredevil taking on the Absorbing Man as he tries to take down NYC with no Avengers to stop him. While that's going on, we learn why Foggy was so keen on partnering with Rosalind Sharpe – she's his biological mother.  And it's Sharpe who thinks Foggy and the firm need to play up Foggy's “best bud” status with Daredevil – which leads to work for the firm as Molten Man (Mark Raxton) seeks help with break-ins at Osborne Chemicals. Daredevil is reunited with the Black Widow as the pair take down the Grey Gargoyle.  We learn a bit about Rosalind's Sharpe's past after Daredevil saves her from an armed man in the firm's lobby then follow's her to visit the gangster responsible.   Next we get a multi-book story involving a new villainous, Insomnia – he's try to keep Daredevil and the rest of New York up at night. We eventually learn she's working for Mr Fear – who himself is causing trouble by enlisting a friend of Molten Man to release a gas during a Osborn Chemicals boardroom meeting which causes Raxton to freak out and start tearing the place apart.  Before we can get a resolution to Mr Fear, we get a Flashback issue of Daredevil (Daredevil #-1) in which Jack Murdock is taking his son Matt to college. This story, from writer Joe Kelly and art by Gene Colan and Matt Ryan is a lot of fun and will be our spotlight story of the week.  Returning back to present time, Daredevil must, once again, deal with Mr Fear's plotting – this time on Ryker's Island when Fear releases a gas to start a prison riot. Daredevil must then take on new and improved Gladiator. (what happened to fear???)  The year ends with a multi-book storyline called “widow's Kiss” that starts with Daredevil helping a firm client who's facing a hostile takeover by the Russians – only to have to tangle Omega Red. Black Widow comes to the aid of Daredevil only to then shoot him herself. She tries then save DD by bring him to Karen for help, before returning to meet with a Russian general we eventually learn she's trying to take down. Despite just being shot, Daredevil goes after Widow and gets the pair captured. The story ends Daredevil escapes and convinces Ursa Major and Vanguard that they are being used by the General – and that he's being running experiments on Vanguards sister – Darkstar.  One other secondary story that ran through much of the year involves Foggy and Liz Osborne. Rosalind Sharpe isn't pleased with their relationship and continually tries to undermine it – with other women. In the final book of the year Foggy and Liz's attempt to have a romantic evening together is derailed when he receives a constant stream of phone calls from other women.  This Week's Spotlight: Daredevil #-1 July 1997 “A Time to Say Farewell”  Recap Why We Picked This Story Daredevil Rapid Fire Questions The Takeaway Marvel messed up more than their own fortunes with their unwise expansions.  Questions or comments We'd love to hear from you!  Email us at questions@comicsovertime.com or find us on Twitter @comicsoftime. ------------------ THANKS TO THE FOLLOWING CREATORS AND RESOURCES  Music: Our theme music is by the very talented Lesfm.  You can find more about them and their music at https://pixabay.com/users/lesfm-22579021/.  The Grand Comics Database: Dan uses custom queries against a downloadable copy of the GCD to construct his publisher, title and creator charts.  Comichron: Our source for comic book sales data.  The American Comic Book Chronicles: Published by TwoMorrows, these volumes provide an excellent analysis of American comics through the years.  Because these volumes break down comic history by year and decade they are a great place to get a basic orientation on what is happening across the comic industry at a particular point in time. 

Sequel is combining the experience of its four co-founders to develop the next generation of insulin pumps, aiming to provide better delivery capabilities, CEO Alan Lotvin tells Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Lotvin sits down with BI analyst Matt Henriksson for an in-depth interview on the path insulin pumps have taken over the past 50 years to close in on a truly automated delivery system. They also discuss Sequel's development of its twiist delivery system, designed to better titrate insulin injected into the body, and its strategy for commercial launch in 2025.See omnystudio.com/listener for privacy information.

“Our mission is to make cancer less deadly through widely accessible next-generation early-detection blood tests.” Susan Tousi, CEO of Delfi Diagnostics, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Tousi joins BI analyst Jonathan Palmer to discuss the company's fragment-based liquid biopsy technology and the immense opportunity to save lives through early cancer detection. Starting with lung cancer via its FirstLook test, Delfi expects to expand more broadly into other cancer types and applications like monitoring with a focus on access and affordability. The conversation touches on the company's core values and the large opportunity set afforded by recent funding rounds.See omnystudio.com/listener for privacy information.

Insulet's Omnipod 5 automated insulin delivery (AID) system has avenues to expand as it's revolutionized the way patients treat their diabetes, including the new indication for Type 2 diabetes, CEO Jim Hollingshead explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Hollingshead sits down with BI analyst Matt Henriksson for an in-depth interview on Insulet's Omnipod patch pump technology, how on-the-body wear compares to traditional insulin pumps and opens access to patients still using syringes, and expansion opportunities with Omnipod 5 in international markets and with the Type 2 diabetic cohort in the US.Find this and other Bloomberg Intelligence podcasts at BI PODCASTS . See omnystudio.com/listener for privacy information.

In this episode of the Wrist Check Podcast, Perri and Rashawn sit down with vintage watch experts Eric Wind and Charlie Dunne, who share exciting news about their upcoming book, The Modern Guide to Vintage Watches. Eric and Charlie discuss their mission to make vintage watches accessible to both seasoned collectors and newcomers, bridging the gap in the market for a comprehensive, yet approachable, guide. They dive into the philosophy and artistry behind collecting, touching on the allure of iconic models, the mystique of tropical dials, and the nuances of watch condition that can drive collector demand. Plus, they reveal insights into pricing rare pieces, like Speedmasters with tropical dials, and explain why details like sharp lugs and unpolished cases matter. Join us for a fascinating look at the evolution of vintage watch collecting, the importance of quality over quantity, and some behind-the-scenes stories about their journey together as co-authors and colleagues in the world of high-end horology. This episode is powered by Bezel. A platform for luxury watches, where you can buy, sell, trade, and even bid on watches up for auction. Follow the links below for more. ⁠⁠⁠Shop 20,000+ watches at get bezel.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Download the Bezel app⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SUBSCRIBE to get the latest Wrist Check Pod content⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Shop our latest collaboration with WOLF 1834, The Shuttle Travel Case available ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Follow us on TikTok⁠⁠ Chapters 00:00 - Intro 01:40 - Wrist Check 07:50 - Collaborating on a book 10:44 - Meeting each other 15:31 - The Esquire Article 18:20 - Discussing Tropical Dials 23:20 - How to price vintage 28:28 - Expanding Client Base 31:08 - Wind Vintage Web Store 33:42 - Modern Watches 38:32 - Moved Coin Watch 40:12 - New surprises in vintage 44:58 - Newbies to vintage watches 46:53 - 1675 GMT Rolex 50:20 - Blueberry GMT Legend 51:44 - Rolex and vintage servicing 54:14 - Buying Opportunities in Vintage 56:16 - Linen Dial DateJust --- Support this podcast: https://podcasters.spotify.com/pod/show/wrist-check-pod/support

“When I looked at the industry, I saw a real opportunity set to build a best-in-class sector-focused fund,” Lynne Chou O'Keefe, founder and managing partner of Define Ventures, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Keefe joins BI analyst Jonathan Palmer for a deep discussion into Define's unique approach to health-care investing, emphasizing the importance of both health-care and tech expertise. The two discuss the major trends shaping health care, including technology, consumerization and the evolution of the value chain. The podcast concludes with insights into the state of the market, including valuations, IPOs and potential consolidation.See omnystudio.com/listener for privacy information.

ClearPoint Neuro is changing brain surgery by developing a suite of new magnetic resonance (MR) navigation technology that aids minimally invasive procedures and drug-delivery capabilities, CEO Joe Burnett explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Burnett sits down with BI analyst Matt Henriksson for an in-depth interview on how the ClearPoint system helps surgeons by leveraging live MR imaging for enhanced accuracy with deep brain stimulation and biopsies. He also outlines plans for a full market release of its PRISM Neuro Laser, and how SmartFlow can help drug delivery, with nearly 50 pharma and biotech partnerships for combination therapy. See omnystudio.com/listener for privacy information.

ResMed's leadership in sleep apnea stems from the combination of its digital-health ecosystem and new hardware to pair with smartwatches and wearables, CEO Mick Farrell tells Bloomberg Intelligence. The mix creates an end-to-end solution for diagnosis of sleep apnea, accelerated patient setup and resupply and proper data management to increase the adherence rate to 80%, he says. In this Vanguards of Health Care episode, Farrell sits down with BI analyst Matt Henriksson for an in-depth interview about how the company started as a spinoff from Baxter to become the market leader in sleep-apnea treatments. Those include novel technologies such as the AirSense 11 continuous positive airway pressure (CPAP) device and n30i mask. Farrell believes the rise of GLPs will have a “Botox effect” on sleep apnea, as patients become more aware of the disease and doctors use all available tools, including ResMed's CPAP devices, to treat it.See omnystudio.com/listener for privacy information.

“Our liquid biopsy test alone, we estimate one in four cancer patients in the US are getting it,” Helmy Eltoukhy, cofounder and co-CEO of Guardant Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Eltoukhy joins BI analyst Jonathan Palmer to discuss the underpinnings of the liquid biopsy revolution and how Guardant has stuck to its technology road map since its founding in 2012, launching products in each of the three major market categories. The conversations also covers the company's recent approval of its Shield colorectal screening test as well as many of the scientific and commercial challenges to standing up the business.See omnystudio.com/listener for privacy information.

Radical Catheter Technologies has developed a new design of catheters that takes ribbon technology of different stiffness (and colors straight out of a Dr. Seuss book) to make a near-infinite amount of transitions for optimized size and structure stability, Chairman Martin Dieck explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Dieck sits down with BI analyst Matt Henriksson to talk about Radical Catheter, how he sees the FDA approval of the 7F Radical Catheter for neurovascular procedures as the first step in the next generation of endovascular access and delivery products, and how he took the efforts to create credibility of the novel technology by building out the intellectual property and manufacturing capacity ahead of time.See omnystudio.com/listener for privacy information.

Listen to a special pledge drive episode featuring show highlights selected by host Kyle Long. Hear interviews with Carlos Santana discussing the influence of Indianapolis guitarist Wes Montgomery, Meshell Ndegeocello on her work with Indianapolis composer Hanna Benn, Omar Apollo recalling his early years in Northwest Indiana, author Tyler Alpern discussing the Indiana LGBTQ+ music pioneer Bruz Fletcher, and much more. Also, hear lost Indiana recordings recovered by Long featuring music from Duke Ellington and The Vanguards.

Listen to a special pledge drive episode featuring show highlights selected by host Kyle Long. Hear interviews with Carlos Santana discussing the influence of Indianapolis guitarist Wes Montgomery, Meshell Ndegeocello on her work with Indianapolis composer Hanna Benn, Omar Apollo recalling his early years in Northwest Indiana, author Tyler Alpern discussing the Indiana LGBTQ+ music pioneer Bruz Fletcher, and much more. Also, hear lost Indiana recordings recovered by Long featuring music from Duke Ellington and The Vanguards.

“Tempus is focused on the idea of bringing technology, and in particular artificial intelligence, to diagnostics by essentially combining a molecular result and then connecting that to clinical data for that patient.” Eric Lefkofsky, Founder and CEO of Tempus AI, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Lefkofsky joins BI analyst Jonathan Palmer for a discussion on how Tempus built a multipurpose platform that generates unique insights not only for treating patients but also in drug discovery and speeding recruitment for clinical trials. The two cover how oncology is just the first beachhead, why it's still early days for the company's data business and the future of using algorithms in treatment.See omnystudio.com/listener for privacy information.

Paragon28 is entering the next chapter of foot and ankle surgery by developing enabling technology that customizes the procedure to the patient and eliminates a one-size-fits-all approach, CEO Albert DaCosta tells Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, DaCosta sits down with BI analyst Matt Henriksson to talk about how the company started from the co-founder's basement, how its technology built a cohesive commercial model to aid foot and ankle surgeons, including product and clinical support, and how it has developed the SMART28 ecosystem that gives surgeons the ability to calculate a patient-specific surgical plan focusing on both bone-reconstruction and soft-tissue balancing. See omnystudio.com/listener for privacy information.

 "If all goes well, Heartbeat Health will be a household name for the first referral from primary care for cardiology. It'll be easier than everyone else out there and less expensive than other referrals." Dr. Jeff Wessler, CEO and Founder of Heartbeat Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wessler joins BI analyst Jonathan Palmer to discuss the genesis of Heartbeat's decentralized cardiology practice, how the company iterated from a brick and mortar clinic to a virtual platform to speed access, and why keeping patient care at the center has improved outcomes.  See omnystudio.com/listener for privacy information.

AVS aims to redefine intravascular lithotripsy with its Pulse IVL System, which utilizes hydraulics technology to fracture calcified lesions and expand the diseased vessel with a single device, executive chair Mark Toland explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Toland sits down with BI analyst Matt Henriksson to discuss what differentiates the Pulse IVL System from current technology to make it more flexible and durable. He also highlights first-in-human results, the next clinical milestones and the mounting market opportunity as an older demographic brings hardened lesions that require IVL technology.See omnystudio.com/listener for privacy information.

Today we talk more about the new Vanguard CEO and Ascensus acquiring Vanguards's individual 401(k) business. We answer a few questions about DAFs and if appreciated securities are a reasonable alternative to DAFs. We talk about donating real estate to charity and then get into detail about contributing to your non dependent adult child's HSA. Today's episode is brought to you by SoFi, helping medical professionals like us bank, borrow, and invest to achieve financial wellness. SoFi offers up to 4.6% APY on their savings accounts, as well as an investment platform, financial planning, and student loan refinancing…featuring an exclusive rate discount for med professionals and $100/month payments for residents. Check out all that SoFi offers at https://www.whitecoatinvestor.com/Sofi *Loans originated by SoFi Bank, N.A., NMLS 696891. Advisory services by SoFi Wealth LLC. The brokerage product is offered by SoFi Securities LLC, Member FINRA/SIPC. Investing comes with risk including risk of loss. Additional terms and conditions may apply. The White Coat Investor has been helping doctors with their money since 2011. Our free financial planning resource covers a variety of topics from doctor mortgage loans and refinancing medical school loans to physician disability insurance and malpractice insurance. Learn about loan refinancing or consolidation, explore new investment strategies, and discover loan programs specifically aimed at helping doctors. If you're a high-income professional and ready to get a "fair shake" on Wall Street, The White Coat Investor is for you! Main Website: https://www.whitecoatinvestor.com  YouTube: https://www.whitecoatinvestor.com/youtube  Student Loan Advice: https://studentloanadvice.com  Facebook: https://www.facebook.com/thewhitecoatinvestor  Twitter: https://twitter.com/WCInvestor  Instagram: https://www.instagram.com/thewhitecoatinvestor  Subreddit: https://www.reddit.com/r/whitecoatinvestor  Online Courses: https://whitecoatinvestor.teachable.com  Newsletter: https://www.whitecoatinvestor.com/free-monthly-newsletter 

Think Surgical's handheld robotic device miniaturizes the level of precision and accuracy orthopedic doctors expect from conventional, bigger surgical platforms, CEO Stuart Simpson explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simpson sits down with BI analyst Matt Henriksson to talk about how the company developed the TMINI robot that provides a pin driver on a gyroscopic handheld for accurate bone resection. This platform eliminates the large form factor of other systems while giving surgeons the choice of which brand of knee implant to use.See omnystudio.com/listener for privacy information.

Has Gerry Beckley retired? Does he still sing with America? Who influenced the band America? All these questions answered this week. Gerry Beckley is a singer/songwriter best known as a founding member of the classic soft rock outfit America. Alongside bandmates Dewey Bunnell and Dan Peek, Gerry first gained recognition for hits like 1971's "Horse with No Name," 1972's "Ventura Highway," 1975's "Sister Golden Hair," and others. Though he and Dewey have continued to perform as America until recenlty, Gery has also recorded under his own name since the mid '90s, releasing such mellow, well-crafted albums as 2022's Aurora and 2024's self -titled album Gerry Beckley. Gerry was born in Texas in 1952. He grew up as the son of an American air force officer and a British mother. Interested in music from a young age, he began playing piano at age three and later added guitar. By the time he was ten, Gerry was a promising musician playing in the surf rock band the Vanguards. He had also come under the influence of The Beatles and other British Invasion-era bands as a result of spending his summer vacations in England. In 1967, Gerry moved with his family to London after his father took over as commander at the United States Air Force base. It was while attending High School that he befriended classmates Dewey Bunnell and Dan Peek. The three quickly formed a band and began performing at a local all-ages club, playing covers by bands like Crosby, Stills and Nash, Neil Young and others. The trio eventually caught the attention of a local promoter and producer, who recorded them and helped them get a record deal. In 1971, they released the single, "A Horse with No Name." A hit the world over, the single propelled the band to early success. With America, Gerry Beckley enjoyed decades of popularity, releasing over 20 albums, touring globally, and penning numerous songs that helped to define both the soft rock and adult contemporary radio formats. Gerry Beckley began to release successful solo material in 1995 with Van Go Gan. The album featured Gerry backed by a bevy of longtime friends and collaborators, including Dewey Bunnell, trumpeter Mark Isham, the Eagles' Timonthy B. Schmit and others. That album was followed by a remix album. Away from America, Gerry next delivered 2000's LIke A Brother- a collaboration with Chicago singer/keyboardist Robert Lamm and the Beach Boys' Carl WIlson who died from lung cancer after completing the album in 1998. The record featured a mix of originals from each member of the band , as well as a cover of Harry Wilson's "Without You" In 2006, Beckley returned with his third solo album, Horizontal Fall. The compilation album Happy Hour was released in 2009. SInce then many solos albums have followed. Gerry has recently married and moved to Sydney Australia where he spends six months of the year. He has resigned from touring with America to concentrate on furthering his solo career. His latest self titled solo album is being touted as his best ever. Gerry plays the bulk of the instruments but gets help from a core group of players that includes former Chicago bassist Jason Scheff, guitarist Steve Fekete, drummers Brian Young and Ryland Steen along with backing vocalists Jeff Larson and Brian Eichenberger. Nick Lane and Matt Combs, also longtime musical fellow travelers, arranged horn and string parts, respectively. It's a collection of 12 original tunes featuring the singles "Red and Blue" and "Well Worn Shoes." Gerry Beckley joins us this week to walk us through his incredible career. For more information head to https://www.gerrybeckley.com/

Asensus Surgical plans to develop augmented intelligence capabilities that digitize surgery to lower variabilities during procedures, drive better results and ultimately expand the adoption of robotics, CEO Anthony Fernando says. In this episode of Bloomberg Intelligence's Vanguards of Health Care podcast, Fernando sits down with BI health care analyst Matt Henriksson to discuss Asensus, the current barriers that keep robotic surgery's penetration rates low and its pending acquisition by Karl Storz. Asensus' product pathway includes the next-generation Luna robotic system, including TrueWrist 5mm instruments as well as enhancements to its Intelligent Surgical Unit.See omnystudio.com/listener for privacy information.

Artificial intelligence is touching all aspects of drug development with a lot of focus, and potential noise, on the early stages of drug discovery. In this episode of Bloomberg Intelligence's Vanguards of Health podcast BI's Head of Global Industries Sam Fazeli discusses the contributions of machine learning, AI and AlphaFold 3 in drug discovery with Harren Jhoti, cofounder of Astex in 1999. Jhoti remains CEO of the group as part of Otsuka Pharmaceuticals. Astex's pioneering work in fragment-based drug discovery has lead to three marketed oncology drugs, including Novartis' Kisqali used for breast cancer. We delve into the steps in which AI can have meaningful impact and what this may mean for saving time in drug development and reducing the risk of drug failure.See omnystudio.com/listener for privacy information.

Eko Health realized that the one tool that every doctor has on their neck, the stethoscope, has not been updated for 200 years, and designed a way for AI to be incorporated for early detection of heart failure, co-founder and CEO Connor Landgraf says. In this episode of Bloomberg Intelligence's Vanguards of Health Care podcast, Landgraf talks with BI analyst Matt Henriksson about how the company was founded and how the Sensora Cardiac Disease Detection Platform can provide early identification of heart failure as a first-of-its-kind non-invasive test. By using algorithms and big data to detect small signals from electrocardiograms that are invisible to physicians, the technology can help shift the overarching trend in health care away from being reactive to patients symptoms, when it may be too late for treatment, and toward detecting disease before symptoms arise.See omnystudio.com/listener for privacy information.

Onward Medical is driving the path to help paraplegics with spinal cord injuries (SCI) regain their lives, including one patient who is now able to play his guitar again, CEO Dave Marver tells Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Marver sits down with BI analyst Matt Henriksson for an in-depth interview about the company, key takeaways from the recent publication of the Uplift trial by Nature and how Onward's developments differ from others that use brain-computer interfaces (BCI). The medical-technology provider connects BCI to its ARC platform to restore movement of the human body, instead of simply using the patient's thoughts to control computer functions.See omnystudio.com/listener for privacy information.

 "We analyze vocal biomarkers in near real time and correlate that to a clinical diagnosis and create an algorithm that then can independently identify a range of different diseases in the human voice during conversation," Henry O'Connell, CEO and Co-founder of Canary Speech, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. O'Connell joins BI analyst Jonathan Palmer to discuss the company's origins, its unique approach to vocal analysis using over 2,500 speech features and its commitment to clinical validation through partnerships with leading healthcare institutions. The conversation touches on Canary's foundational team, extensive patent portfolio and platform approach that enables the development of models for a wide range of diseases. See omnystudio.com/listener for privacy information.

EDAP can treat prostate cancer by focusing ultrasound waves at just the target region, similar to how a magnify glass can focus light from the sun so intensely that it can burn a piece of paper, allowing it to eliminate the cancer while limiting side effects, CEO Ryan Rhodes explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Rhodes sits down with BI analyst Matt Henriksson to talk about his path from Intuitive Surgical to lead EDAP, how the Focal One robot uses high intensity focused ultrasound, or HIFU, to ablate prostate cancer without needing an incision or removing the whole prostate and how the HIFI Study shows that Focal One can be a viable alternative to radical prostatectomy.See omnystudio.com/listener for privacy information.

Haemonetics, a medical-device maker that focuses on markets including blood and plasma collection, is evolving to expand broadly with more diversification and greater sustainability over time, all with the view that good products win, CEO Chris Simon explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simon sits down with BI analyst Matt Henriksson to talk about Haemonetics and how its has built out its hospital franchise with M&A to include high-growth segments that diversifies the company beyond its traditional blood and plasma collection businesses. He also shares his views on how medtech companies need to have products with competitive advantages as the hospital environment rationalizes and whittles down the number of medtech suppliers they use.See omnystudio.com/listener for privacy information.

OrthoPediatrics' aspiration is to develop anatomically appropriate implants, instruments and specialized braces for children, so surgeons don't need to “MacGyver” their way with treating a child with adult sized devices, CEO David Bailey explains to Bloomberg Intelligence, referring to the multi-skilled character from the 1980s TV series. In this Vanguards of Health Care podcast episode, Bailey sits down with BI analyst Matt Henriksson for an in-depth interview to talk about OrthoPediatrics, how its technology built a cohesive commercial model to aid pediatric orthopedic surgeons, including products and clinical support, and how it has developed a strong M&A platform to add innovation to its portfolio.See omnystudio.com/listener for privacy information.